Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- HIV -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (112)	8/14/2009 7:31:37 PM
From: DewDiligence_on_SI	1 Recommendation Read Replies (1) \| Respond to of 155

I give the TMC278+Truvada combination a slight edge over GILD’s Quadro to become the new SoC in HIV—not because it’s better, but rather because it’s sooner: siliconinvestor.com

To: idos who wrote (112)	8/14/2009 8:14:32 PM
From: Elroy Jetson	Read Replies (1) \| Respond to of 155

Elvitegravir is more potent than Isentress (raltegravir) on resistant viral isolates T66I, L74M, E92Q, F121Y, Q148K, S153Y, and N155H. This should result in greater durability of elvitegravir provided there has not been prior use of Isentress. pubs.acs.org In practice elvitegravir will be widely used at the 800 mg bid dosing first trialed to avoid the use of a ritonavir-like drug, even though much effort has been put into developing GS9350. Patient tolerability of ritonavir is quite low, less than 75%, and most who "tolerate" the drug are happier without it. Gilead has refused to comment on the tolerability and side-effect profile of GS9350 alone. Another ritonavir competitor developed by Sierra Pharmaceuticals is described as "well tolerated" with the common side-effects being nausea, vomiting, severe headaches and diarrhea - similar to the list associated with ritonavir. The FDA would prefer a ritonavir-like enzyme substrate, but there is little urgency in this as there is no evidence that the low doses of ritonavir used provides a signififcant enough barrier to exert selection pressure. The clinical use of these drugs is highly divergent from the labelling and advertising. .